Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
EPRX · Why this verdict
Why Eupraxia Pharmaceuticals (EPRX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Eupraxia is a pre-revenue, cash-burning biotech with 110.4% upside to the analyst target, but quality is weak (1.6/10), the earnings record is poor (2 misses and 2 in-line results in the last 4 reports), and the stock sits in a downtrend.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
As a $0.5B small cap in a binary biotechnology industry, Eupraxia sits below institutional reach, with outcomes concentrated in a few trial results. Suitability rationale | Institutional ownership builds as the pipeline matures over 12 months, lifting the stock's visibility. | →Stable |
| CounterSmall-cap biotechs with no revenue frequently see sharp drawdowns, and being below institutional reach limits the buyers who could support the price. | ||
Eupraxia is cash-burning with negative free cash flow, no competitive moat, and zero revenue in all 5 reported quarters, leaving quality at 1.6 versus a 4.0 floor. Quality breakdown | Cash burn is funded through the next 12 months and quality rises above 4.0 only if the pipeline begins generating revenue. | →Stable |
| CounterZero revenue and negative cash flow mean a dilutive financing could come at any time, and nothing in the data shows a revenue source in the next year. | ||
The $14.45 analyst target is 110.4% above the $6.87 price, though coverage is light. Analyst target | Price moves toward the $14.45 target as pipeline milestones are reached over 12 months. | →Stable |
| CounterLight coverage dampens the signal, and biotech targets are tied to binary trial outcomes; a failure would cut the target by far more than the 13.6% modeled downside. | ||
Eupraxia has missed EPS estimates in 2 of the last 4 reports, including a 133.3% miss on 2026-03-12, with an average surprise of -57.6%. Last 4 quarters | EPS losses come in at or narrower than estimates at the 2026-11-03 report, ending the pattern of misses. | ↑Improving |
| CounterLosses are widening against estimates as spending rises, and the next report in 10 days could add another miss. | ||
Momentum is weak at 3.9/10 with price below its 200-day average, though that average is still rising 2.3% per 30 days and on-balance volume shows accumulation. Momentum breakdown | Price reclaims its 200-day average and momentum rises above 4.5 from 3.9. | ↓Deteriorating |
| CounterTechnical signals are mixed with no clear pattern, and a binary biotech can break the uptrend on a single trial update. | ||
As a $0.5B small cap in a binary biotechnology industry, Eupraxia sits below institutional reach, with outcomes concentrated in a few trial results.
→StableSuitability rationale
- Expectation
- Institutional ownership builds as the pipeline matures over 12 months, lifting the stock's visibility.
CounterSmall-cap biotechs with no revenue frequently see sharp drawdowns, and being below institutional reach limits the buyers who could support the price.
Eupraxia is cash-burning with negative free cash flow, no competitive moat, and zero revenue in all 5 reported quarters, leaving quality at 1.6 versus a 4.0 floor.
→StableQuality breakdown
- Expectation
- Cash burn is funded through the next 12 months and quality rises above 4.0 only if the pipeline begins generating revenue.
CounterZero revenue and negative cash flow mean a dilutive financing could come at any time, and nothing in the data shows a revenue source in the next year.
The $14.45 analyst target is 110.4% above the $6.87 price, though coverage is light.
→StableAnalyst target
- Expectation
- Price moves toward the $14.45 target as pipeline milestones are reached over 12 months.
CounterLight coverage dampens the signal, and biotech targets are tied to binary trial outcomes; a failure would cut the target by far more than the 13.6% modeled downside.
Eupraxia has missed EPS estimates in 2 of the last 4 reports, including a 133.3% miss on 2026-03-12, with an average surprise of -57.6%.
↑ImprovingLast 4 quarters
- Expectation
- EPS losses come in at or narrower than estimates at the 2026-11-03 report, ending the pattern of misses.
CounterLosses are widening against estimates as spending rises, and the next report in 10 days could add another miss.
Momentum is weak at 3.9/10 with price below its 200-day average, though that average is still rising 2.3% per 30 days and on-balance volume shows accumulation.
↓DeterioratingMomentum breakdown
- Expectation
- Price reclaims its 200-day average and momentum rises above 4.5 from 3.9.
CounterTechnical signals are mixed with no clear pattern, and a binary biotech can break the uptrend on a single trial update.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 6.1 |
| OBV | 5.8 |
| MA position | 7.0 |
| Volume | 0.0 |
- ▸Above 200-day MA
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.8 |
| Analyst rating | 8.0 |
| Price target | 10.0 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 125%
Insider
5.0/10data confidence 50%Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 1.2 |
| growth rank | 5.0 |
Technical
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.4 |
| support resistance | 6.4 |
| 52w position | 5.8 |
Risk (lower is worse)
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| days to cover | 3.1 |
| volatility | 0.0 |
| beta | 6.1 |
| debt equity | 9.9 |
Catalyst
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 6.0 |
- ▸Earnings concerns: 0B/2M
- ▸Earnings in 5 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:4.9>=4.5
- ASYMMETRY:7.4>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:5d<=7d
Warning (1)
- MOMENTUM:4.9<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
7.37
Upside
+95.8%
Downside
13.0%
Sizing output
AVOID
SetupRange Bound — RSI 48 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the EARNINGS_PROXIMITY gate's 5d<=7d outcome against Value at 9.0 and asymmetric R:R of 7.37.
The strongest dimensions are Value at 9.0, Sentiment at 7.9, and Technical at 5.5; the weakest are Quality at 1.6, Catalyst at 3.2, and Peer rank at 4.6. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 7.37 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burn No Revenue
Trip ifQuality score falls below 1.0 from current 1.6, or cash runway drops to less than 4 quarters.
- P2Analyst Target Upside
Trip ifAnalyst target falls below $9 from current $14.45.
- P3Poor Earnings Record
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P4Pullback Below Trend
Trip ifPrice falls below the $6.39 stop level, more than 7% under the current $6.87.
- P5Binary Biotech Small Cap
Trip ifShare price falls more than 40% from $6.87 on a negative trial readout.